Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: The example of liposomal all-trans retinoic acid [2]

Blood

Volumn 105, Issue 3, 2005, Pages 1366-1367

  Estey, Elihu ^a   Koller, Charles ^b   Tsimberidou, Apostolia M ^b   O'Brien, Susan ^b   Beran, Miloslav ^b   Cortes, Jorge ^b   Tirado Gomez, Maribel ^b   Lopez Berestein, Gabriel ^b   Kantarjian, Hagop ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IDARUBICIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ACUTE LEUKEMIA; CANCER CHEMOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LETTER; LEUKOCYTE COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELAPSE; REMISSION; THROMBOCYTE COUNT;

EID: 12844253650     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3437     Document Type: Letter

References (5)

1. Estey EH, Giles FJ, Kantarjian H, et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:2230-2235.
2. Estey E, Koller C, Cortes J, et al. Treatment of newly diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid. Leuk Lymphoma. 2000;42:309-316.
3. DeLima M, Strom S, Keating M, et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood. 1997;90:4719-4724.
4. Sanz MA, Lo Coco F, Martin G. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253.
5. Estey E, Faderl S, Giles F, et al. All-trans retinoic acid + arsenic trioxide to minimize or eliminate chemotherapy in untreated APL [abstract]. Blood. 2003;102:618a.